CY1122264T1 - Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων - Google Patents

Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων

Info

Publication number
CY1122264T1
CY1122264T1 CY20191101159T CY191101159T CY1122264T1 CY 1122264 T1 CY1122264 T1 CY 1122264T1 CY 20191101159 T CY20191101159 T CY 20191101159T CY 191101159 T CY191101159 T CY 191101159T CY 1122264 T1 CY1122264 T1 CY 1122264T1
Authority
CY
Cyprus
Prior art keywords
treatment
fibrotic diseases
ppar compounds
ppar
compounds
Prior art date
Application number
CY20191101159T
Other languages
English (en)
Inventor
Irena Konstantinova
Jean-Michel Luccarini
Jean-Louis Junien
Pierre Broqua
Original Assignee
Inventiva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventiva filed Critical Inventiva
Publication of CY1122264T1 publication Critical patent/CY1122264T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η εφεύρεση αφορά τη χρήση ενός pan-PPAR αγωνιστή, ή μιας φαρμακευτικής σύνθεσης που περιέχει τον αναφερθέντα αγωνιστή, για την αντιμετώπιση μιας ινωτικής κατάστασης.
CY20191101159T 2014-06-13 2019-11-06 Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων CY1122264T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP14305895 2014-06-13
EP14305896 2014-06-13
EP14305894 2014-06-13
EP14305897 2014-06-13
EP14307187 2014-12-24
PCT/EP2015/063196 WO2015189401A1 (en) 2014-06-13 2015-06-12 Ppar compounds for use in the treatment of fibrotic diseases.

Publications (1)

Publication Number Publication Date
CY1122264T1 true CY1122264T1 (el) 2020-11-25

Family

ID=53373480

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101159T CY1122264T1 (el) 2014-06-13 2019-11-06 Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων

Country Status (24)

Country Link
US (2) US10052311B2 (el)
EP (1) EP3154543B1 (el)
JP (1) JP6557684B2 (el)
KR (1) KR102347721B1 (el)
CN (1) CN106573058B (el)
AU (1) AU2015273454B2 (el)
BR (1) BR112016029129A2 (el)
CA (1) CA2951337C (el)
CY (1) CY1122264T1 (el)
DK (1) DK3154543T3 (el)
EA (1) EA036342B1 (el)
ES (1) ES2755183T3 (el)
HR (1) HRP20191941T1 (el)
HU (1) HUE046293T2 (el)
IL (1) IL249458B (el)
MX (1) MX2016016534A (el)
PL (1) PL3154543T3 (el)
PT (1) PT3154543T (el)
RS (1) RS59426B1 (el)
SI (1) SI3154543T1 (el)
TN (1) TN2016000535A1 (el)
UA (1) UA120851C2 (el)
WO (1) WO2015189401A1 (el)
ZA (1) ZA201608281B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53114A (fr) * 2018-07-13 2021-05-19 Kinarus Ag Combinaisons d'agonistes de ppar et d'inhibiteurs de kinase p38 pour prévenir ou traiter des maladies fibrotiques
FR3084254B1 (fr) * 2018-07-27 2020-10-23 Inventiva Derives deuteres du lanifibranor
CN110934866B (zh) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 西格列羧及其相关化合物的应用
US11504380B2 (en) 2019-11-08 2022-11-22 Inventiva Method of treatment of cirrhosis
WO2021161218A1 (en) * 2020-02-11 2021-08-19 Inorbit Therapeutics Ab Sulfinic acid and sulfonic acid compounds for use in modulating peroxisome proliferator-activated receptors
EP4000616A1 (en) 2020-11-17 2022-05-25 Inventiva Combination therapy for the treatment of a liver disease
WO2022122014A1 (zh) 2020-12-11 2022-06-16 苏州科睿思制药有限公司 Lanifibranor的晶型及其制备方法和用途
CN114058694A (zh) * 2021-11-29 2022-02-18 上海市普陀区中心医院 Trpv1在筛选或制备预防、缓解和/或治疗肝脏疾病的药物中的应用
KR20230143965A (ko) 2022-04-06 2023-10-13 (주)샤페론 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 폐섬유증 예방 또는 치료용 조성물
WO2023220332A1 (en) * 2022-05-13 2023-11-16 Children's Hospital Medical Center Methods and compositions for treatment of idiopathic pulmonary fibrosis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070092488A1 (en) 2003-05-16 2007-04-26 Intermune Inc. Methods of treating idiopathic pulmonary fibrosis
FR2890071B1 (fr) * 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
CA2621474A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1,3-disubstituted indole derivatives for use as ppar modulators
JP2007112720A (ja) * 2005-10-18 2007-05-10 Kissei Pharmaceut Co Ltd メタボリックシンドローム予防又は治療薬
JP5248747B2 (ja) * 2006-01-19 2013-07-31 キッセイ薬品工業株式会社 アディポネクチン受容体発現賦活薬
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
EP2229951A1 (en) 2009-03-08 2010-09-22 Stichting Katholieke Universiteit Methods for the treatment or prevention of systemic sclerosis
ES2681794T3 (es) 2009-11-26 2018-09-17 Genfit Uso de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos
ME02207B (me) 2010-05-26 2016-02-20 Adverio Pharma Gmbh UPOTREBA sGC STIMULATORA, sGC AKTIVATORA, POJEDINAČNO I U KOMBINACIJI SA PDE5 INHIBITORIMA ZA TRETMAN SISTEMSKE SKLEROZE (SSc)
US9572787B2 (en) 2011-05-19 2017-02-21 Rhode Island Hospital Inhibition of renal fibrosis
CN107375291A (zh) 2011-10-28 2017-11-24 鲁美纳医药公司 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
WO2013071077A1 (en) * 2011-11-09 2013-05-16 Cornell University The use of pan-ppar agonists for prevention and treatment of huntington's disease and tauopathies
US20150184155A1 (en) 2012-07-18 2015-07-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for preventing and treating chronic kidney disease (ckd)

Also Published As

Publication number Publication date
US20180333396A1 (en) 2018-11-22
US10383858B2 (en) 2019-08-20
UA120851C2 (uk) 2020-02-25
US10052311B2 (en) 2018-08-21
JP6557684B2 (ja) 2019-08-07
TN2016000535A1 (en) 2018-04-04
KR102347721B1 (ko) 2022-01-05
BR112016029129A2 (pt) 2018-01-30
KR20170042504A (ko) 2017-04-19
CA2951337A1 (en) 2015-12-17
PL3154543T3 (pl) 2020-02-28
AU2015273454B2 (en) 2019-09-05
CN106573058B (zh) 2020-05-05
EA036342B1 (ru) 2020-10-29
HUE046293T2 (hu) 2020-02-28
WO2015189401A1 (en) 2015-12-17
RS59426B1 (sr) 2019-11-29
CA2951337C (en) 2022-08-23
EP3154543A1 (en) 2017-04-19
CN106573058A (zh) 2017-04-19
ZA201608281B (en) 2018-05-30
PT3154543T (pt) 2019-11-04
MX2016016534A (es) 2017-04-06
ES2755183T3 (es) 2020-04-21
IL249458B (en) 2020-08-31
EA201692433A1 (ru) 2017-05-31
US20170189383A1 (en) 2017-07-06
AU2015273454A1 (en) 2017-01-05
EP3154543B1 (en) 2019-08-28
IL249458A0 (en) 2017-02-28
JP2017524663A (ja) 2017-08-31
HRP20191941T1 (hr) 2020-01-10
SI3154543T1 (sl) 2019-12-31
DK3154543T3 (da) 2019-12-02

Similar Documents

Publication Publication Date Title
CY1122264T1 (el) Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201691582A1 (ru) Новые фармацевтические препараты
DK3218509T3 (da) Mutante mikroorganismer, der er resistente over for lactose-drab
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MY192927A (en) Fused bicyclic compounds for the treatment of disease
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
EA201692534A1 (ru) Способы лечения гипотонии
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
DK3145530T3 (da) Trail receptor agonists for treatment of fibrotic diseases
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
BR112016027455A2 (pt) moduladores ppar
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
EA201691493A1 (ru) Замещенные n-арилпиридиноны
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
DOP2017000001A (es) Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer
PH12016502466A1 (en) Ppar compounds for use in the treatment of fibrotic diseases
TN2014000522A1 (fr) لوح مدرسي بوجهين
PT2933251T (pt) Composição farmacêutica que pode ser utilizada para o tratamento de uma patologia do pé de um mamífero ungulado
TH1601003570A (th) สารประกอบใหม่สำหรับการรักษาภาวะน้ำตาลในเลือดต่ำอย่างรุนแรง